Patent · US Active

Fibroblast growth factor-21-Fc fusion proteins

US9006400B2 · kind B2 · utility

55Cited by

1References

7Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Brian R. Boettcher · Winchester, US
Shari Lynn Caplan · Lunenburg, US
Douglas S. Daniels · Arlington, US
Norio Hamamatsu · Belmont, US
Stuart Licht · Cambridge, US
Stephen Craig Weldon · Leominster, US

Key dates

Filing date	Sep 25, 2012
Grant date	Apr 14, 2015
Priority date	—
Expiry date	Sep 25, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.